Abivax S.A.
ABVXAbivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Drugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Sep 14, 2026
6wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
ABX464
Ulcerative Colitis
ABX203 therapeutic Hepatitis B vaccine treatment arm
Chronic Hepatitis B
Obefazimod
Moderately to Severely Active Crohn Disease
ABX464 100 mg
Ulcerative Colitis
ABX464 150mg
HIV Infections
ABX464 50mg
Rheumatoid Arthritis
ABX196
Carcinoma, Hepatocellular
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ABX464 | Phase 3 | Ulcerative Colitis | - | - |
ABX203 therapeutic Hepatitis B vaccine treatment arm | Phase 3 | Chronic Hepatitis B | - | - |
Obefazimod | Phase 2 | Moderately to Severely Active Crohn Disease | - | - |
ABX464 100 mg | Phase 2 | Ulcerative Colitis | - | - |
ABX464 150mg | Phase 2 | HIV Infections | - | - |
ABX464 50mg | Phase 2 | Rheumatoid Arthritis | - | - |
ABX196 | Phase 2 | Carcinoma, Hepatocellular | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Abivax S.A.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Abivax S.A.'s (ABVX) pipeline across Phase 3, Phase 2. Its lead program is ABX464 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Abivax S.A.'s next FDA catalyst?→
Abivax S.A.'s (ABVX) next tracked catalyst is a Earnings expected September 14, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ABVX biotech catalysts?→
Add ABVX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Abivax S.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.